The safety and efficacy of changing from either cyclosporine or tacrolimus to RAPAMUNE® in maintenance kidney transplant patients have not been established.Please see full Prescribing Information, including Medication Guide and Boxed Warning, available at www.RAPAMUNE.com.
Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE® (sirolimus) In Renal Transplant Recipients
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts